In September 2025, Exactech, Inc., a Florida‑based medical‑device company, came to an agreement to pay US $8 million. The reason is clear to the masses now across the country. The company has violated the federal False Claims Act by selling defective knee implant devices and making false claims to federal health programs. The settlement reveals not only the failures of knee implant devices but also the risks the patients encounter. This blog sheds light on the background, allegations, settlement drivers, and Exactech lawsuit implications.
Background on Exactech and its Knee Implant Business
Exactech, Inc., based in Gainesville, Florida, manufactures orthopedic implants (knee implant devices) and surgical instruments. Over the past few years, the company has steadily stepped into the global market, supplying joint replacement devices, such as knee implant devices. A total-knee replacement system includes a tibial tray (a metal component) and a polyethylene insert (a plastic component).
Hundreds of knee replacements are performed annually in the U.S. In most cases, the device’s guarantee and lifespan are critical concerns for hospitals, doctors, and patients. Exactech’s share in the company’s products competes directly with other major orthopedic implant makers.
Defects in the Knee‑Implant Devices
The settlement reveals two major defective parts of Exactech’s knee devices –
The Finned tibial tray: The government alleged that as early as January 2008, Exactech became aware that this component failed at an early stage only. However, it continued to be marketed and sold in the surgical market between January 1, 2008, and December 31, 2018.
The Polyethylene Component: By January 2019, Exactech was already aware that these plastic inserts had failed prematurely and were therefore not approved for use in total knee replacement surgeries on federal health program beneficiaries. And yet, the company continued to market these systems between January 1, 2019, and February 7, 2022.
The allegations have raised concerns about the durability and the potential impact of the implants on patients. When a component fails, it may lead to revision surgery and care, which can impose costs, risks, and burdens on the patient and the healthcare system.
The False Claims Act allegations and Government Action
Under the Federal False Claims Act (FCA), Federal Healthcare Programs (such as Medicare, Medicaid, and the U.S. Department of Veterans Affairs) receive claims for goods or services that are needed for the patient’s treatment. The government has held Exactech liable for knowingly selling components that could fail prematurely and has reimbursed federal programs for surgeries involving the defective knee implant devices. As the Exactech Lawsuit Update 2025 is concerned, let’s have a look at the allegations made against the manufacturer.
As the U.S. Department of Justice has declared, Exactech Inc. agreed to pay $8 million to resolve these allegations. Of that amount, approximately $7.64 million represented the federal‑share component, and approx. $360,000 was allotted to state shares.
Additionally, whistleblower lawsuits were also part of the case. Private individuals were also sued on behalf of the government under the FCA. The settlement provides for approximately $1,329,360 to the Alabama whistleblowers and $565,360 to the Maryland whistleblower.
It’s important tonote that Exactech did not admit liability in the settlement.
Why Exactech Agreed to Pay?
Several factors influenced Exactech’s decision to settle for $8 million. Let’s see what they are:
Reputation and Monetary Risks: The allegations involve key components of knee implant devices. If found liable, the consequences could be too severe for the company.
Bankruptcy Status: Exactech is currently under Chapter 11 bankruptcy proceedings, due to mass-tort litigation related to implant recalls (over 2,500 patient injury claims) and other liability exposures. In this situation, if the company offers a defined settlement, it may help the company manage a portion of its risk exposure and simplify its go‑forward path.
Government and Whistleblower Pressure: Whistleblower lawsuits and FCA enforcement lead to substantial penalties and intense public scrutiny.
Cost-Benefit Considerations: Although $8 million is a high settlement amount, it may be far less than the potential expenses, litigation costs, and business obstruction associated with a full trial. The settlement may lead to future uncertainty.
Final Takeaway
Exactech’s $8 million settlement, which aims to resolve allegations under the False Claims Act, has several downsides in the system. Patients who have undergone the defective knee implant will be under strict vigilance. The Exactech lawsuit serves as a caution to manufacturers regarding the reliability of devices and the need for prompt corrective action. The Exactech case serves as a reminder that in healthcare, particularly in the field of implantable medical devices, the stakes are high. Hence, it’s wiser to be cautious each time devices are implanted at the manufacturing units. To know further about the Exactech Lawsuit Update 2025, keep in touch with People for Law. Our attorneys are Here for USA, Here for You.
